Form 4: Akari Therapeutics Director Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Samir Rashmikant Patel, a Director and 10% owner of Akari Therapeutics Plc, reported multiple transactions in common stock on July 7, 2026.

Summary

  • Option exercise/conversion: acquired 1,209 American Depositary Shares representing Ordinary Shares at $8.00 ($9,672) on July 7, 2026; holds 76,976 after (Indirect).
  • Option exercise/conversion: acquired 15,466 American Depositary Shares representing Ordinary Shares at $0.00 ($6) on July 7, 2026; holds 92,442 after (Indirect).
  • Option exercise/conversion: acquired 5,799 American Depositary Shares representing Ordinary Shares at $0.00 ($2) on July 7, 2026; holds 98,241 after (Indirect).
  • Option exercise/conversion: acquired 1,209 Pre-Funded Warrant to purchase American Depositary Shares at $32.00 ($38,688) on July 7, 2026 (Indirect).
  • Option exercise/conversion: acquired 15,466 Pre-Funded Warrant to purchase ADSs at $16.16 ($249,931) on July 7, 2026 (Indirect).
  • Option exercise/conversion: acquired 5,799 Pre-Funded Warrant to purchase ADSs at $16.16 ($93,712) on July 7, 2026 (Indirect).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Samir Rashmikant Patel — Director, 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-07-07Option exercise/conversionAmerican Depositary Shares representing Ordinary Shares1,209$8$9.7K76,976
2026-07-07Option exercise/conversionAmerican Depositary Shares representing Ordinary Shares15,466$0$692,442
2026-07-07Option exercise/conversionAmerican Depositary Shares representing Ordinary Shares5,799$0$298,241
2026-07-07Option exercise/conversionPre-Funded Warrant to purchase American Depositary Shares1,209$32$38.7K0
2026-07-07Option exercise/conversionPre-Funded Warrant to purchase ADSs15,466$16$249.9K0
2026-07-07Option exercise/conversionPre-Funded Warrant to purchase ADSs5,799$16$93.7K0

Key Dates

DateDescription
2026-07-07Option exercise/conversion (1,209 shares)
2026-07-07Option exercise/conversion (15,466 shares)
2026-07-07Option exercise/conversion (5,799 shares)
2026-07-07Option exercise/conversion (1,209 shares)
2026-07-07Option exercise/conversion (15,466 shares)
2026-07-07Option exercise/conversion (5,799 shares)

Keywords

insider transaction, Form 4, AKTX, Akari Therapeutics Plc, neutral, Samir Rashmikant Patel

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.